Contrary to the perceptions given by the increased awareness of ED, Premature Ejaculation ("PE") is probably the most common form of male sexual dysfunction. The Global Study of Sexual Attitudes and Behaviour, published in 2003, reported an overall global prevalence rate in men of 21.4%. This suggests that the potential market opportunity for a treatment for PE could exceed the size of the ED market. In 2005, prescription ED treatments had combined annual sales of approximately US $3 billion.
PE is a complex and often overlooked sexual disorder. Whilst ED sufferers now have access to treatments, information and support, there is currently no licenced treatment for PE and relatively little information and support available to PE sufferers. In these respects the situation is similar to that of ED sufferers 10 years ago, pre-Viagra®.
PE can be difficult to define. It is often commonly referred to as "coming too soon". The American Urological Association use the following definition: "ejaculation that occurs sooner than desired either before or shortly after penetration, causing distress to either one or both partners". Unlike ED it is a problem encountered by men of all ages, with no significant variation linked to age. Men who have suffered all their lives are referred to as "primary sufferers" whilst those who suffer from this condition later in their lives are referred to as "secondary sufferers". Many men will have encountered the problem of premature ejaculation occasionally or on a situational basis, for example when dating a new partner or when going through stressful times.
There are currently no clinically proven licensed products available over the counter for PE, making PET500 potentially the first such product. A number of pharmaceutical companies are developing products for this indication but none have been approved in Europe or the USA.